Evidence map›Paper›PMID 28185098›Full record

ReviewJournal of industrial microbiology & biotechnology2017

Advancement in bioprocess technology: parallels between microbial natural products and cell culture biologics.

Arpan A Bandyopadhyay, Anurag Khetan, Li-Hong Malmberg, Weichang Zhou, Wei-Shou Hu

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of industrial microbiology & biotechnology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Arpan A BandyopadhyayDepartment of Chemical Engineering and Materials Science, University of Minnesota, 421 Washington Avenue SE, Minneapolis, MN, 55455-0132, USA.
Anurag KhetanBiological Process Development, Bristol Myers Squibb, 521 NJ-173, Bloomsbury, NJ, 08804, USA.
Li-Hong MalmbergAbbVie Bioresearch Center, 100 Research Drive, Worcester, MA, 01605, USA.
Weichang ZhouWuXi AppTec, Pudongxin District, Shanghai, China.
Wei-Shou HuDepartment of Chemical Engineering and Materials Science, University of Minnesota, 421 Washington Avenue SE, Minneapolis, MN, 55455-0132, USA. acre@cems.umn.edu.ORCID 0000-0002-5964-2900

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The emergence of natural products and industrial microbiology nearly eight decades ago propelled an era of bioprocess innovation. Half a century later, recombinant protein technology spurred the tremendous growth of biologics and added mammalian cells to the forefront of industrial producing cells in terms of the value of products generated. This review highlights the process technology of natural products and protein biologics. Despite the separation in time, there is a remarkable similarity in their progression. As the new generation of therapeutics for gene and cell therapy emerges, its process technology development can take inspiration from that of natural products and biologics.

Indexed as

AnimalsBiological FactorsBiological ProductsBiotechnologyCell Culture TechniquesHumansIndustrial MicrobiologyRecombinant ProteinsBiological FactorsBiological ProductsRecombinant ProteinsNatural productsProcess technologyProtein biologics

Identifiers

PMID28185098

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.